Martin Huber
2021 - Xilio Therapeutics
In 2021, Martin Huber earned a total compensation of $3.5M as President of R&D and Chief Medical Officer at Xilio Therapeutics, a 259% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $269,325 |
|---|---|
| Option Awards | $2,720,568 |
| Salary | $458,859 |
| Other | $11,272 |
| Total | $3,460,024 |
Huber received $2.7M in option awards, accounting for 79% of the total pay in 2021.
Huber also received $269.3K in non-equity incentive plan, $458.9K in salary and $11.3K in other compensation.
Rankings
In 2021, Martin Huber's compensation ranked 3,872nd out of 12,406 executives tracked by ExecPay. In other words, Huber earned more than 68.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,872 out of 12,406 | 69th |
Division Manufacturing | 1,585 out of 5,492 | 71st |
Major group Chemicals And Allied Products | 648 out of 2,368 | 73rd |
Industry group Drugs | 576 out of 2,089 | 72nd |
Industry Pharmaceutical Preparations | 403 out of 1,536 | 74th |
Source: SEC filing on April 26, 2022.
Huber's colleagues
We found two more compensation records of executives who worked with Martin Huber at Xilio Therapeutics in 2021.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Xilio Therapeutics CEO René Russo's 2023 pay jumps 36% to $3M
April 25, 2024
Xilio Therapeutics CEO René Russo's 2022 pay falls 60% to $2.2M
April 25, 2023
Xilio Therapeutics CEO René Russo's 2021 pay jumps 118% to $5.5M
April 26, 2022